
Science/Research reporter
Lisa Krieger
Lisa M. Krieger is a Bay Area News Group science writer for The Mercury News and East Bay Times, covering research, scientific policy and environmental news from Stanford University, the University of California, NASA-Ames, U.S. Geological Survey and other Bay Area-based research facilities. She graduated from Duke University with a BA degree in biology. She splits her time between Palo Alto and Inverness, and in her spare time likes wildlife photography, swimming, skiing and backpacking.
All Stories

A clue to long COVID? UCSF discovery of persistent viral fragments could guide the search for treatment.

SUBSCRIBER ONLY
Long Covid creates changes in the blood, aiding detection, reports new study
A shifting pattern of proteins, showing immune dysregulation, could help efforts to create diagnostic tests and treatment.

SUBSCRIBER ONLY
Bird flu infects Petaluma’s historic poultry region, putting small farmers in peril
The Avian virus has barreled through a bucolic Petaluma valley, inflicting heartbreak and economic disaster on poultry farms forced to euthanize thousands of birds to curb the outbreak.

Who will need a Yosemite reservation as park revives restrictions
Overwhelmed by last year’s crowds, Yosemite National Park will limit entry next spring, summer and fall.

New psychedelic-like drugs: All treatment, no 'trip'?
California scientists race to concoct compounds that rewire the brain without euphoria or hallucinations.

Psychedelic drugs: Follow the money as investors seek to replace Prozac, Zoloft and other drugs
Biotech startups and venture capital funds are investing in once-controversial treatments.

SUBSCRIBER ONLY
Paradise recovery from deadly Camp Fire: How to build a fireproof town
Atop a windswept ridge between two wild canyons, the town of Paradise is rebuilding for a hotter, drier climate -- an inspiration for other California towns at risk of nature’s...

SUBSCRIBER ONLY
CRISPR could kill HIV. But we don't know if it's a cure.
The potential treatment, called EBT-101, is safe and caused no major side effects, Excision BioTherapeutics reported at a meeting in Brussels.

SUBSCRIBER ONLY
A pioneering gene therapy aims to free patients of blood disease. Is a cure at hand?
After years of blood transfusions, "they think getting cured is totally normal," said Alissa Finlayson.

SUBSCRIBER ONLY
How a rare dementia unleashes creativity
Brain scans reveal why some patients with frontotemporal dementia show a burst of visual creativity.